Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Digital Realty Trust | Eli Lilly and Company | Meta Platforms | |
|---|---|---|---|
| Moat rating | narrow The FY2025 10-K's own competitive record cuts both ways. Item 1 says a "high-quality, highly interconnected global portfolio such as ours could not be easily replicated today on a cost-competitive basis," yet Item 1A concedes that competitors have "significantly greater financial, marketing and other resources and more ready access to capital" and that as rivals keep developing space, "rental rates may be reduced or we may face delays in leasing." A durable advantage that its own filing says new supply can price against is bounded, not unassailable. | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow The FY2025 10-K shows a real moat — 3.58 billion Family daily active people (December 2025 average, +7% YoY) and a 52% Family of Apps operating margin — but the same filing qualifies its durability on three fronts it discloses itself: it says "We face significant competition in every aspect of our business"; it names "competitive products and services, such as TikTok, that have reduced some users' engagement with our products and services"; and it discloses that since 2020 it has been "subject to a lawsuit by the FTC alleging that we violated antitrust laws" that "seeks ... divestiture or reconstruction of Instagram and WhatsApp." A moat a regulator is actively litigating to break up, and whose ad targeting depends on iOS/Android policies Meta does not set, reads narrow rather than wide. |
| Moat type | network effects Item 1 attributes the hard-to-replicate part of the portfolio to connectivity rather than to real estate: "the network density, interconnection infrastructure and connectivity-centric customers in certain of our data centers have led to the organic formation of densely connected data communities that are difficult for competitors to replicate." That community sits on over 232,000 cross connects in over 55 metros, so each network and cloud that lands makes the same building worth more to the next tenant. | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | network effects The 10-K Competition section describes a three-sided network in Meta's own words: it competes "to attract, engage, and retain people who use our products, to attract and retain businesses that use our free or paid business and advertising services, and to attract and retain developers who build compelling applications that integrate with our products," and elsewhere cites "the scale of our user, advertiser, and developer base." The same filing rules out an IP-based moat: "We do not believe that our proprietary technology is dependent on any single patent or copyright or groups of related patents or copyrights." |
| Leadership | co leader Item 1 claims the title of "the largest global provider of cloud- and carrier-neutral data center, colocation and interconnection solutions," but the Competition section names Equinix and NTT as operators of properties "similar to ours in some of the same metropolitan areas," plus Global Switch and regional operators abroad — a shared top tier on the company's own telling, not a solitary one. | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | co leader Top-tier but shared: the 10-K reports 3.58 billion Family daily active people and $196.18 billion of 2025 advertising revenue, yet also states that TikTok has "reduced some users' engagement," that "each of Apple and Google have integrated competitive products with iOS and Android," and that Meta competes "with companies in the development and application of AI, particularly with respect to the development of frontier AI models." |
| Pricing power | strong FY2025 renewals signed re-priced upward in every bucket — +27.0% on greater-than-1 MW space ($146 to $186 per square foot), +4.6% on 0-1 MW ($268 to $280) and +43.0% on other ($49 to $71) — and MD&A expects average aggregate rental rates on 2026 renewals to be positive against the rates currently paid for the same space "on a GAAP basis and on a cash basis." On costs, the filing says utilities expense "is our largest expense category" and that "the vast majority of the expense is passed directly through to our customers," which it credits with significantly mitigating exposure to power-cost increases rather than removing it. The cap: Item 1A warns competitor development could still force rates down. | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | strong Ad-auction pricing, not list prices: the 10-K reports "the average price per ad increased by 9%" in 2025 after "an increase of 10% in 2024," driven by "an increase in advertising demand," alongside worldwide ARPP of $57.03 (+15%) and a 52% Family of Apps operating margin. The filing notes the gain was "partially offset by a higher number of ad impressions delivered ... in products, such as Reels, that monetize at lower rates." |
| Summary | Digital Realty rents space, power and connectivity rather than compute: at 2025 year-end its portfolio held 310 data centers and roughly 57.6 million rentable square feet across more than 55 metros in over 30 countries, about 84.7% leased, serving more than 5,000 customers. Two different businesses sit inside that footprint. The greater-than-1 MW wholesale side is a capital-and-power race — 769 MW of projects underway with 64% pre-leased, and land that "could accommodate over 3,500 megawatts of additional data center capacity" — where the 10-K names Equinix, NTT, Global Switch and "various private operators" as rivals and warns that added supply can push rents down. The colocation and interconnection side is the defended half: over 232,000 cross connects and the "densely connected data communities" Item 1 says competitors cannot easily replicate, reinforced by contracts the filing describes as generally running 5-10+ years on large deployments and by improvements "installed at our customers' expense." FY2025 leasing supports that read — renewals signed re-priced +27.0% on greater-than-1 MW space and +4.6% on 0-1 MW — while customer concentration is the offsetting exposure, with the largest customer at roughly 11.7% of annualized recurring revenue. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Meta's advantage is the size of the user-advertiser-developer network it monetizes, not proprietary technology: 3.58 billion daily active people across the Family of Apps produced $196.18 billion of 2025 advertising revenue at a 52% segment operating margin, and the 10-K attributes 2025's 9% rise in average price per ad to "an increase in advertising demand, which we believe is mostly due to ongoing improvements to our ad performance from our ad targeting and measurement tools." The filing is equally explicit about what limits that network: TikTok has "reduced some users' engagement," Apple's iOS changes "limit our ability ... to target and measure ads effectively," the April 2025 European Commission decision against its "subscription for no ads" model pushed EU users onto less personalized ads that are "less relevant and effective," and the FTC is seeking divestiture of Instagram and WhatsApp. Reality Labs, the intended next platform, lost $19.19 billion in 2025 on $2.21 billion of revenue and is expected "to continue to operate at a loss for the foreseeable future." |
| Chain position | Landlord to the AI stack — sells the space, power and interconnection that cloud, network and enterprise tenants run compute in (Oracle, IBM, Meta Platforms, AT&T, Comcast and Lumen are among the customers named in Item 1), with roughly 2.9 GW of total in-place IT capacity. | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Demand-side anchor of the AI build-out: the 10-K reports $72.22 billion of 2025 capital expenditures and says Meta has "designed and built our own data centers and key portions of our technical infrastructure," funded entirely by the advertising business. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.17 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.17 at weight 0.20 · swarm neutral Editorial prior, not backtested. |